Sensitive fluorescent quantitation of myo-inositol 1,2-cyclic phosphate and myo-inositol 1-phosphate by high-performance thin-layer chromatography

A non-radioactive micro-assay for the cyclic phosphodiesterase reaction catalyzed by Bacillus cereus phosphatidylinositol-specific phospholipase C is described. The assay involves high-performance thin-layer chromatography on silica gel to resolve the substrate (myo-inositol 1,2-cyclic phosphate) and the product (myo-inositol 1-phosphate), followed by detection with a lead tetraacetate–fluorescein stain. The quantitation of these inositol phosphates in sample spots relative to a series of standards is accomplished by analysis of the fluorescent plate image with a commercial phosphoimager and associated software. The experimental considerations for reliable quantitation of inositol monophosphates in the range of 0.1 to 50 nmol are presented.     

Synthesis of L-chiro-inositol 1,4,6-trisphosphorothioate, a potent and selective inhibitor of myo-inositol 1,4,5-trisphosphate 5-phosphatase

L-chiro-inositol 1,4,6-trisphosphate and trisphosphorothioate have been synthesized from L-quebrachitol; the trisphosphorothiate is the most potent inhibitor of Ins(1,4,5)P₃ 5-phosphatase yet discovered.     

Total synthesis of L-2,2-difluoro-2-deoxy-MYO-inositol 1,4,5-trisphosphate, a potent inhibitor of the enzymes of d-MYO-inositol 1,4,5-trisphosphate metabolism

The synthesis of the enantiomers of 2,2-difluoro-2-deoxy-myo-inositol 1,4,5-trisphosphate is reported. L-2,2-difluoro-2-deoxy-myo-inositol 1,4,5-trisphosphate is a potent inhibitor of 3-kinase and 5-phosphatase.     

Myo-inositol 1,4,6-trisphosphate: A new synthetic Ca-mobilising inositol phosphate

The synthesis of myo-inositol 1,4,6-trisphosphate from myo-inositol is described; this novel trisphosphate is a potent Ca²⁺-mobilising agonist at the Ins(1,4,5)P₃ receptor and is derived from structure-activity considerations of myo-inositol 1,3,4,6-tetrakisphosphate.     

The phosphorylation status and cytoskeletal remodeling of striatal astrocytes treated with quinolinic acid

Quinolinic acid (QUIN) is a glutamate agonist which markedly enhances the vulnerability of neural cells to excitotoxicity. QUIN is produced from the amino acid tryptophan through the kynurenine pathway (KP). Dysregulation of this pathway is associated with neurodegenerative conditions. In this study we treated striatal astrocytes in culture with QUIN and assayed the endogenous phosphorylating system associated with glial fibrillary acidic protein (GFAP) and vimentin as well as cytoskeletal remodeling. After 24 h incubation with 100 µM QUIN, cells were exposed to ³²P-orthophosphate and/or protein kinase A (PKA), protein kinase dependent of Ca²⁺/calmodulin II (PKCaMII) or protein kinase C (PKC) inhibitors, H89 (20 μM), KN93 (10 μM) and staurosporin (10 nM), respectively. Results showed that hyperphosphorylation was abrogated by PKA and PKC inhibitors but not by the PKCaMII inhibitor. The specific antagonists to ionotropic NMDA and non-NMDA (50 µM DL-AP5 and CNQX, respectively) glutamate receptors as well as to metabotropic glutamate receptor (mGLUR; 50 µM MCPG), mGLUR1 (100 µM MPEP) and mGLUR5 (10 µM 4C3HPG) prevented the hyperphosphorylation provoked by QUIN. Also, intra and extracellular Ca²⁺ quelators (1 mM EGTA; 10 µM BAPTA-AM, respectively) prevented QUIN-mediated effect, while Ca²⁺ influx through voltage-dependent Ca²⁺ channel type L (L-VDCC) (blocker: 10 µM verapamil) is not implicated in this effect. Morphological analysis showed dramatically altered actin cytoskeleton with concomitant change of morphology to fusiform and/or flattened cells with retracted cytoplasm and disruption of the GFAP meshwork, supporting misregulation of actin cytoskeleton. Both hyperphosphorylation and cytoskeletal remodeling were reversed 24 h after QUIN removal. Astrocytes are highly plastic cells and the vulnerability of astrocyte cytoskeleton may have important implications for understanding the neurotoxicity of QUIN in neurodegenerative disorders.     

Use of phosphorus-32 labeled polyphosphoric acid for synthesis of labeled purine and pyrimidine 5'-ribonucleotides

Phosphorus-32 labeled polyphosphoric acid was used to phosphorylate the 2′,3′-O-isopropylidene derivaties of purine and pyrimidine ribonucleosides. The reaction mixture, which contained isopropylidene ribonucleoside 5′-phosphates, was subjected to selective hydrolysis, which removed the isopropylidene protecting group. The polyphosphate chains remained intact. Chromatography revealed the presence of ribonucleoside 5′-mono-, di-, tri-, tetra-, and higher phosphates. The distribution of radioactive label was established by liquid scintillation counting and enzyme assay. The triply labeled adenosine triphosphate prepared in this manner proved to be enzymically active and gave a positive firefly bioluminescence response.     

The influence of lysophosphatidic acid on platelet protein phosphorylation

Lysophosphatidic acid (LPA) is a lysophospholipid that is produced during thrombin stimulation of platelets, which can promote platelet aggregation. The mechanism of the effect of LPA was explored in normal platelets and in platelets from a patient with a storage pool deficiency (SPD). A comparison with other lysophospholipids showed that only LPA exerted significant effects to cause or potentiate platelet aggregation. Aspirin, an inhibitor of prostaglandin endoperoxide synthetase, had little effect on LPA-induced aggregation, but completely blocked LPA-induced serotonin secretion. LPA also promoted phosphorylation of myosin light chain (MLC), a 47 kilodalton (kDa) protein, and actin-binding protein. Aspirin significantly inhibited the phosphorylation of the 47-kDa and actin-binding proteins at 3-8 min after the addition of LPA, but had no effect on protein phosphorylation within the 1st min and had no significant effect on MLC phosphorylation. In SPD platelets, aspirin partially inhibited both aggregation and phosphorylation of the 47-kDa protein (less than 30% inhibition) and MLC (less than 40% inhibition) at time points of 1 min or less. The addition of ADP to SPD platelets enhanced the LPA response in platelets either pretreated or not pretreated with aspirin. Studies with SPD platelets indicate that thromboxane and secreted ADP contribute to, but are not necessary for, LPA-induced aggregation and phosphorylation. A23187 (a calcium ionophore) and LPA showed some selectivity to promote MLC as opposed to the 47-kDa protein phosphorylation, particularly at low concentrations of agonists and at earlier time points. The protein phosphorylation changes seen are consistent with a role for MLC phosphorylation in the granule centralization promoted with LPA.     

Mitochondrial oxidative phosphorylation at Site I involving a fatty aldehyde/acid couple

A mechanism for respiration and oxidative phosphorylation at Site I is proposed which involves reduction by NADH of a thioester of a fatty acid to aldehyde. Oxidation of the aldehyde by non-heme iron forms fatty acid which initially binds to a membrane base. As the non-heme iron reduces, entropy is lost through the stretching of a lipid bilayer attached to the non-heme iron and the membrane and to which the fatty acid chain binds. Simultaneously energy is expended in separating carboxyl ion from the protonated base. The charge separation induces movements of protons and reactants which result in the formation of ATP. Subsequent oxidation of non-heme iron relaxes the stretched lipid and the entropy gain in the fatty acid contributes to reformation of its thioester. The mechanism accounts in detail for many observations.     

The effect of retinoic acid on protein phosphorylation in mouse melanoma cells

Vitamin A inhibits growth and increases the activity of cAMP-dependent protein kinase in B16 mouse melanoma cells. In this report we show that retinoic acid (RA) treatment of intact cells alters their subsequent in vitro protein phosphorylation, but we could not demonstrate any changes in in vivo protein phosphorylation. A 48-h treatment with RA results in a concentration-dependent decrease of protein phosphorylation of a 95K molecular weight (MW) protein in both supernatant and particulate fractions. The phosphorylation of this protein does not appear to be regulated by cAMP. Proteins at 92K and 82K MW in the supernatant fraction are increased in phosphorylation. The former (but not the latter) is regulated by cAMP. In the particulate fraction a variety of proteins 12K-68K MW are increased in phosphorylation, as the cells are treated with increasing amounts of RA. The phosphorylation of most of these proteins is regulated by cAMP. Another inhibitor of B16 cell growth, melanocyte-stimulating hormone (MSH) also alters protein phosphorylation. At short incubation periods (1 h), this hormone stimulates phosphorylation of a number of proteins (17-40K MW), while in longer incubation periods (48 h) phosphorylation is inhibited. All of these phosphorylations appear to be regulated by cAMP. We attempted to repeat these observations using intact-cell phosphorylation with 32PO4. In two experiments we saw small changes in the phosphorylation of proteins. In most experiments, however, we could find no change in the phosphoproteins. Further experiments have led us to question the in vivo phosphorylation, since treatment of the cells with MSH, cholera toxin, or db-cAMP also did not affect intact-cell protein phosphorylation. We have previously documented that under these latter conditions cAMP levels are greatly elevated and cAMP-dependent protein kinase is activated. The in vitro phosphorylation results suggests that in RA-treated cells, kinase activities and/or protein substrate levels are changing. However, the physiological significance of the particular MW phosphoproteins changes we have described must await resolution of the in vivo phosphorylation data.     

The phosphorus/oxygen ratio of mitochondrial oxidative phosphorylation.

The transport of ATP out of mitochondria and uptake of ADP and Pi into the matrix are coupled to the uptake of one proton (Klingenberg, M., and Rottenberg, H. (1977) Eur. J. Biochem. 73, 125--130). According to the chemiosmotic hypothesis of oxidative phosphorylation this coupling of nucleotide and Pi transport to proton transport implies that the P/O ratio for the synthesis and transport of ATP to the external medium is less than the P/O ratio for the synthesis of ATP inside mitochondria. A survey of previous determinations of the P/O ratio of intact mitochondria showed little convincing evidence in support of the currently accepted values of 3 with NADH-linked substrates and 2 with succinate. We have measured P/O ratios in rat liver mitochondria by the ADP pulse method and by 32 Pi esterification, measuring oxygen uptake with an oxygen electrode, and find values close to 2 with beta-hydroxybutyrate as substrate and 1.3 with succinate as substrate in the presence of rotenone to inhibit NADH oxidation. These values were largely independent of pH, temperature, Mg2+ ion concentration, Pi concentration, ADP pulse size, or amount of mitochondria used. We suggest that these are the true values of the P/O ratio for ATP synthesis and transport by mitochondria, and that previously reported higher values resulted from errors in the determination of oxygen uptake and the use of substrates which lead to ATP synthesis by succinate thiokinase.     

蛋白磷酸化去磷酸化与突触囊泡循环

神经递质合成酶、胞吐相关蛋白、神经递质受体,以及离子通道等蛋白的磷酸化和去磷酸化对神经系统的功能具有重要作用。神经递质的释放往往伴随众多蛋白的磷酸化或去磷酸化过程,包括突触蛋白磷酸化引起突触囊泡从细胞骨架上解离、突触囊泡通过复合体SNARE和Ca2 的介导与突触前膜发生锚靠、融合和神经递质释放,以及以网格蛋白依赖的形式实现突触囊泡从突触前膜上内陷、出芽和缢缩后,从膜上裂解到胞浆中重新形成突触囊泡。因此,蛋白磷酸化和去磷酸化对于神经系统完成神经信号传递具有重要的意义。